ANDA 91079, held by Teva Pharms USA. Olmesartan Medoxomil.
As of Nov 15, 2026, ANDA 91079 (Olmesartan Medoxomil), held by Teva Pharms USA, was first approved by FDA on Apr 24, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 24, 2017 | Original application | Approved | None posted |
| Olmesartan Medoxomil5MG · tablet;oral | Olmesartan Medoxomil | Discontinued |
| Olmesartan Medoxomil20MG · tablet;oral | Olmesartan Medoxomil | Discontinued |
| Olmesartan Medoxomil40MG · tablet;oral | Olmesartan Medoxomil | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
